Special Price for Rivaroxaban - Venetoclax 1257044-40-8 – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our firm aims to operating faithfully, serving to all of our consumers , and working in new technology and new machine continually for Doxycycline Hyclate En Español, Doxycycline Hyclate For Toothache, Apixaban Manufacturer, We play a leading role in providing customers with high quality products good service and competitive prices.
Special Price for Rivaroxaban - Venetoclax 1257044-40-8 – CPF Detail:

维奈妥拉 Venetoclax 1257044-40-8 In-House
    VCL-6A 98549-88-3 In-House
    VCL-7A 1235865-75-4 In-House
    VCLM2 1228780-72-0 In-House
    VCLM2-2HCl 1628047-87-9 In-House
    VCLM3 1228779-96-1 In-House

Generic Name: venetoclax (ven ET oh klax)
Brand Name: Venclexta, Venclexta Starting Pack

Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.

Venetoclax is used in combination with azacitidine, decitabine, or cytarabine to treat acute myeloid leukemia. This combination is for use in adults who are 75 years or older, or who cannot use standard chemotherapy due to other medical conditions.

Venetoclax is sometimes given after other treatments have failed.

Venetoclax may also be used for purposes not listed in this medication guide.

Description

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy.

In Vitro

Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC50=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC50=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC50=3 nM) but is much less effective against BCL-XL-BCL-XS (EC50=2.2 μM) or MCL-1-NOXA complexes.

After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGImax) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05)[1].

Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden.

Storage

Powder

-20°C

3 years

4°C

2 years
In solvent

-80°C

6 months

-20°C

1 month

Chemical structure

Venetoclax 1257044-40-8

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation


Product detail pictures:

Special Price for Rivaroxaban - Venetoclax 1257044-40-8  – CPF detail pictures


Related Product Guide:

Our business puts emphasis on the administration, the introduction of talented personnel, as well as the construction of team building, trying hard to further improve the standard and liability consciousness of staff members customers. Our enterprise successfully attained IS9001 Certification and European CE Certification of Special Price for Rivaroxaban - Venetoclax 1257044-40-8 – CPF , The product will supply to all over the world, such as: Hyderabad, Dominica, Lisbon, We will supply much better products with diversified designs and professional services. At the same time, welcome OEM, ODM orders, invite friends at home and abroad together common development and achieve win-win, integrity innovation, and expand business opportunities! If you have any question or need more information please feel free to contact us. We are looking forward to receiving your enquiries soon.
  • With a positive attitude of "regard the market, regard the custom, regard the science", the company works actively to do research and development. Hope we have a future business relationships and achieving mutual success.
    5 Stars By Gail from Qatar - 2017.03.28 12:22
    This is the first business after our company establish, products and services are very satisfying, we have a good start, we hope to cooperate continuous in the future!
    5 Stars By Diana from Portland - 2017.11.20 15:58
    Write your message here and send it to us